GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Cyclically Adjusted PB Ratio

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted PB Ratio?

As of today (2024-04-27), SELLAS Life Sciences Group's current share price is $1.46. SELLAS Life Sciences Group's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2,414.04. SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio or its related term are showing as below:

SLS's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.715
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SELLAS Life Sciences Group's adjusted book value per share data for the three months ended in Dec. 2023 was $-0.248. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2,414.04 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio falls into.



SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.46/2414.04
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, SELLAS Life Sciences Group's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.248/129.4194*129.4194
=-0.248

Current CPI (Dec. 2023) = 129.4194.

SELLAS Life Sciences Group Quarterly Data

Book Value per Share CPI Adj_Book
201403 11,833.079 99.695 15,361.228
201406 7,185.533 100.560 9,247.733
201409 7,619.506 100.428 9,819.113
201412 8,578.472 99.070 11,206.461
201503 11,211.385 99.621 14,564.894
201506 9,158.627 100.684 11,772.528
201509 6,003.148 100.392 7,738.940
201512 2,502.407 99.792 3,245.337
201603 2,048.350 100.470 2,638.551
201606 3,342.270 101.688 4,253.738
201609 3,346.853 101.861 4,252.341
201612 -493.287 101.863 -626.735
201703 1,098.304 102.862 1,381.867
201706 766.306 103.349 959.610
201709 524.964 104.136 652.424
201712 17.947 104.011 22.331
201803 -10.708 105.290 -13.162
201806 -16.815 106.317 -20.469
201809 45.014 106.507 54.698
201812 11.906 105.998 14.537
201903 6.101 107.251 7.362
201906 7.159 108.070 8.573
201909 2.338 108.329 2.793
201912 1.199 108.420 1.431
202003 1.200 108.902 1.426
202006 0.563 108.767 0.670
202009 0.840 109.815 0.990
202012 1.962 109.897 2.311
202103 1.905 111.754 2.206
202106 2.105 114.631 2.377
202109 1.676 115.734 1.874
202112 1.280 117.630 1.408
202203 0.253 121.301 0.270
202206 0.927 125.017 0.960
202209 0.612 125.227 0.632
202212 0.231 125.222 0.239
202303 0.465 127.348 0.473
202306 0.171 128.729 0.172
202309 -0.135 129.860 -0.135
202312 -0.248 129.419 -0.248

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SELLAS Life Sciences Group  (NAS:SLS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


SELLAS Life Sciences Group Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Executives
Angelos M. Stergiou director, officer: President and CEO C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood officer: EVP, Gen. Counsel, Corp. Sec. 58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns officer: VP, Finance & Corp Controller 16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano officer: Chief Commercial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis officer: Chief Medical Officer and SVP C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri director C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd 10 percent owner O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Headlines

From GuruFocus

SELLAS Life Sciences Announces Proposed Underwritten Public Offering

By sperokesalga sperokesalga 02-23-2023